Bicara Therapeutics Management
Management criteria checks 1/4
Bicara Therapeutics' CEO is Claire Mazumdar Clemon, appointed in Jan 2020, has a tenure of 4.67 years. total yearly compensation is $4.54M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $5.37M. The average tenure of the management team and the board of directors is 1.7 years and 1.5 years respectively.
Key information
Claire Mazumdar Clemon
Chief executive officer
US$4.5m
Total compensation
| CEO salary percentage | 9.9% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.7yrs |
| Board average tenure | 1.5yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$5m | US$450k | -US$52m |
Compensation vs Market: Claire's total compensation ($USD4.54M) is about average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Insufficient data to compare Claire's compensation with company performance.
CEO
Claire Mazumdar Clemon (35 yo)
4.7yrs
Tenure
US$4,543,323
Compensation
Ms. Claire Mazumdar Clemon, PhD, M.B.A., serves as Chief Executive Officer and Director of Bicara Therapeutics Inc since January 2020 and served as its President. She served as Senior Associate at Third Ro...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.7yrs | US$4.54m | 0.39% $ 5.4m | |
| President | 3.9yrs | US$3.16m | 0.20% $ 2.8m | |
| Chief Financial Officer | 3.5yrs | US$2.48m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
| SVP of R&D Strategy and Operations | no data | no data | no data | |
| Senior VP and Head of Technical Operations & Supply Chain | 1.7yrs | no data | no data | |
| Chief Medical Officer | 1.2yrs | no data | 0.065% $ 903.1k | |
| VP & Head of Regulatory Affairs | 1.7yrs | no data | no data | |
| Senior Vice President of Clinical & Medical Affairs | less than a year | no data | no data | |
| Senior Vice President of Quality | no data | no data | no data |
1.7yrs
Average Tenure
48yo
Average Age
Experienced Management: BCAX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.7yrs | US$4.54m | 0.39% $ 5.4m | |
| President | no data | US$3.16m | 0.20% $ 2.8m | |
| Independent Chairman of the Board | less than a year | no data | no data | |
| Non-Executive Independent Director | 5.4yrs | US$150.66k | 0.031% $ 424.1k | |
| Board Observer | no data | no data | no data | |
| Independent Director | 5.8yrs | no data | 0.83% $ 11.4m | |
| Independent Director | less than a year | US$175.90k | 0% $ 0 | |
| Director | 1.5yrs | no data | no data | |
| Independent Director | less than a year | US$175.90k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Non-Executive Independent Director | less than a year | no data | no data | |
| Non Executive Independent Director | 1.5yrs | no data | no data |
1.5yrs
Average Tenure
48yo
Average Age
Experienced Board: BCAX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.